Cystic Fibrosis Foundation - Click here for homepage
Stay Informed  |  Volunteer  |  Clinical Trials

In This Section

Quick Links

Find a Chapter

Get Assistance

Get Assistance - Cox Boys
We are here to help people with CF get the insurance coverage they need. Hear how the Foundation helped the Cox family.

Join us on Facebook!  Facebook 
Follow us on Twitter!   Twitter
Follow us on Instagram!  Instagram 
Add us to your circle in Google+!

Google+ 

Subscribe to our channel on YouTube!  YouTube  


 

 

Print  

Transave Announces Positive Phase 2 Results for Arikace™ in the Treatment of Pseudomonas Lung Infections

June 17, 2008

Transave, Inc., this week reported positive results from a Phase II clinical trial on its lead investigational drug, Arikace™ (liposomal amikacin for inhalation). The compound is being developed for the treatment of cystic fibrosis patients who have lung infections due to the bacterium Pseudomonas aeruginosa.

The Phase II data indicated that Arikace, delivered once daily for 28 consecutive days, produced a significant improvement in lung function, was well-tolerated, and had a side-effect profile comparable to placebo. The Phase II trial was a randomized, double-blind, placebo-controlled study of 64 patients from 15 centers in Europe.

Cystic Fibrosis Foundation Therapeutics, the nonprofit affiliate of the Cystic Fibrosis Foundation, provided a $1.7 million award to support the development of Arikace.

Read the full press release.

GFC Holiday Promo

The Cystic Fibrosis Foundation is an accredited charity of the Better Business Bureau.